Nutritional Supplementation of Vitamin D, Quercetin and Curcumin With Standard of Care for Managing Mild Early Symptoms of COVID-19

• Status: Recruiting
• Trial end date: 2021-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate the therapeutic benefits of combination of nutritional supplements of Vit D, Quercetin and Curcumin with standard of care for managing mild early symptoms of COVID-19.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: King Edward Medical University

Criteria

Inclusion Criteria:

• Patients must be 18 years of age or older, of either gender

• Patients must be tested positive for SARS-CoV-2 by RT-PCR

• Patients must exhibit typical symptoms of COVID-19 disease at screening such as fever, fatigue, a dry and contagious cough, loss of appetite, body aches, shortness of breath, mucus or phlegm, sore throat, headache, chills, sometimes withshaking, loss of smell or taste, congestion or runny nose, nausea, or vomiting, diarrhea, muscular pain etc.

• Patients must be in the early stage of COVID-19 disease who do not require hospitalization at the time of screening

• Patients must be under the care of a Physician for diagnosis of COVID-19

• Patients who have signed informed consent

Exclusion Criteria:

• Patients with proven hypersensitivity or allergic reaction to quercetin or curcumin

• Patients with known chronic kidney disease with estimated creatinine clearance < 50 mL/minute or need for dialysis

• Patients who are severely hypotensive defined as needing hemodynamic pressors to maintain blood pressure

• Patients taking anticoagulant/antiplatelet drugs such as Coumarine, Heparine, Aspirin, Clopidrogel, dalteparin, enoxaparin, ticlopidine and warparin.

• Patients with gallstone obstruction

• Hypothyroid suppering patients

• Patients with moderate or severe thrombocytopenia (platelet count <100 ×10⁹/L);

• Pregnant patients